How much revenue does Chengdu Kanghong Pharmaceutical Group make?

Chengdu Kanghong Pharmaceutical Group reported 4.45 billion CNY in revenue for fiscal year 2024, up 12.5% from 3.96 billion CNY in fiscal year 2023. In Q2 2025 revenue was 1.25 billion CNY.

Where does Chengdu Kanghong Pharmaceutical Group make most of its revenue?

East China: 27% of revenue by region in fiscal year 2025, followed by South China (25%).

What companies are similar to Chengdu Kanghong Pharmaceutical Group?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS), Beijing Tiantan Biological Products Co., Ltd. (600161.SS), Hualan Biological Engineering Inc. (002007.SZ), Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS).

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) Stock

About Chengdu Kanghong Pharmaceutical Group Co., Ltd

Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.

At a glance

Chengdu Kanghong Pharmaceutical Group reported revenue of 4.45 billion CNY for fiscal year 2024, up 12.5% from fiscal year 2023, and net income of 1.19 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 1.25 billion CNY, up 4.5% from a year before. East China was its largest region in fiscal year 2025, with 27% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.